Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643929 · ClinicalTrials.gov registry record
LENS - Long-term Eltrombopag Observational Study
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 164
- Enrollment target
NCT00643929 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 164 participants.
The verdict
NCT00643929 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.
Interventions
- DRUG Eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00643929
The ClinicalTrials.gov registry entry for NCT00643929 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eltrombopag is the first listed.
NCT00643929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00643929 about?
NCT00643929 is a clinical study titled "LENS - Long-term Eltrombopag Observational Study". A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (r...
What is the current status of trial NCT00643929?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2007-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00643929?
The interventions under investigation include: Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT00643929?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.